Saturday, November 23, 2024
HomeTagsFDA Acceptance

FDA Acceptance

CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis

CymaBay Therapeutics, Inc., a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, announced that the U.S. Food and...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics